期刊文献+

载体材料对泊沙康唑肠溶片结晶抑制效果的研究

Study on the Inhibitory Effect of Carrier Materials on the Crystallization of Posaconazole Enteric Tablets
下载PDF
导出
摘要 目的使用不同载体材料制备泊沙康唑固体分散体及肠溶片,评估载体材料对抑制药物释放后重结晶的能力。方法分别采用羟丙甲纤维素琥珀酸酯、尤特奇L100或尤特奇L100-55制备成固体分散体的肠溶片,通过体外溶出实验中加入泊沙康唑原料作为晶种诱导结晶,评估在晶种诱导环境下评估不同载体材料抑制重结晶的能力。结果体外溶出曲线结果证明,三种材料制备的泊沙康唑肠溶片对结晶抑制的能力各有差异,其中羟丙纤维素琥珀酸酯与尤特奇L100-55效果较优,尤特奇L100次之。结论筛选出具有结晶抑制能力的载体材料,为泊沙康唑肠溶片开发提供借鉴。 OBJECTIVE To evaluate the inhibition ability of recrystallization after drug release of Posaconazole solid dispersions and enteric tablets,which prepared with different carrier materials.METHODS An enteric tablet of solid dispersion was prepared using hypromellose succinate,Eudragit L100 or Eudragit L100-55 respectively,and evaluated by an in vitro dissolution method which developed to evaluate the inhibition ability of recrystallization with different carrier materials in a seed-induced environment.RESULTS The in vitro dissolution curve showed the Posaconazole enteric tablets prepared by the three materials had different crystallization inhibition ability.Among which hydroxypropylcellulose succinate and Eudragit L100-55 were superior.CONCLUSION Screening for carrier materials that can be used in the hot melt extrusion process with satisfactory crystallization inhibition ability and for reference to develop Posaconazole Enteric tablets.
作者 梁兆丰 冯思欣 李伟 LIANG Zhao-feng;FENG Si-xin;LI Wei(Bostal Drug Delivery Co.,Ltd,Guanzhou 510530,China)
出处 《海峡药学》 2020年第9期11-13,共3页 Strait Pharmaceutical Journal
基金 广东省引进创新创业团队专项资金资助项目(2014ZT05Y018) 广州市产业领军人才聚集工程项目(CYLJTD-201604)。
关键词 泊沙康唑 热熔挤出 肠溶片 结晶抑制 Posaconazole Hot melt extrusion Enteric tablets Crystallization inhibition
  • 相关文献

参考文献4

二级参考文献97

  • 1杨睿,唐星,黄惠锋.热熔挤出技术提高水飞蓟素溶出度的初步研究[J].中国新药杂志,2005,14(11):1305-1308. 被引量:25
  • 2杨睿,唐星,黄惠锋.热熔挤出技术及其在药物传递系统中的应用[J].中国新药杂志,2007,16(4):279-284. 被引量:26
  • 3Vehreschild J J, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with a- cute myelogenous leukaemia (AMID : a 6 year experience of the Cologne AML cohort [J]. J Antimicrob Chemother, 2010,65(7) : 1466-1471.
  • 4Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posacon- azole vs itraconazole in allogeneic blood and marrow trans- piantation[J]. Bone Marrow Transplant, 2011,46(5) : 733- 739.
  • 5Winston DJ, Bartoni K, Territo MC, et al. Efficacy, safety, and breakthrough infections associated with standard long- term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients[J]. Biol Blood Marrow Trans- plant, 2011,17(4) :507-515.
  • 6Zoller E, Valente C, Baker K, et al. Development, clinical u- tility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections[J]. Drug Des DeveI T her, 2010,4:299- 311.
  • 7Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet[J], Br J Haematol, 2011,153(6):681-697.
  • 8Walsh TJ, Raad I, Patterson TF, et aI. Treatment of inva- sire aspergillosis with posaconazole in patients who are refrae tory to or intolerant of conventional therapy: an externally controlled trial[J]. Clin Infect Dis, 2007,44(1):2- 12.
  • 9Raad II, Hanna HA, Boktour M, et al. Novel antifungal a-gents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphoteriein B alone or in combination with caspofungin [J]. Leukemia, 2008,22 (3) 496-503.
  • 10Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity[J]. Am J Health Syst Pharm, 2009,66(3) :225-236.

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部